SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

BACKGROUND: Demand for a future HIV vaccine, similar to other vaccines, is vulnerable to misinformation. A number of studies have examined HIV vaccine acceptability and demand, but few have systematically...

Background: Recent systematic reviews have demonstrated the efficacy of doxycycline prophylaxis in preventing bacterial sexually transmitted infections (STIs) in randomised controlled trials (RCTs). In this review, we updated evidence from RCTs...

Background Dolutegravir (DTG) is endorsed as a preferred option for both first- and second-line antiretroviral therapy (ART); however, comprehensive high-quality evidence regarding its virological effectiveness is still limited. This review...

With the widespread use of antiretroviral therapy (ART), the life expectancy of people living with HIV (PLWH) has significantly improved. However, the incidence of cardiovascular disease (CVD) in this population...

Background: The combination of doravirine and islatravir (DOR/ISL) is a novel two-drug regimen for HIV-1. Early development faced challenges due to dose-dependent immunological signals. We aimed to synthesize the evidence on...

Community responses are essential to achieving the global goal of Ending AIDS by 2030, yet men who have sex with men (MSM) remain underrepresented and often tokenized within HIV initiatives....

Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and...

The widespread use of combination antiretroviral therapy has transformed HIV infection into a chronic condition, with life expectancy of people with HIV (PWH) approaching that of the general population when...

Co-infection of HIV and HBV is still a major global public health concern. Co-infected people have a nearly threefold increased risk of end-stage liver disease, with a noticeably faster development...

INTRODUCTION: Despite significant efforts to manage and prevent HIV, knowledge gaps persist regarding mother-to-child transmission of HIV among women of reproductive age. Previous studies, limited in scope and producing inconsistent...

Introduction Tuberculosis (TB), a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (PLHIV), accounted for 161,000 deaths among HIV-co-infected patients in 2023. Tuberculosis preventive therapy...

Rationale In 2007, WHO issued emergency recommendations on empiric treatment of sputum acid-fast bacillus (AFB) smear-negative patients with possible tuberculosis (TB) in HIV-prevalent areas, and called for operational research to...